The Role of Preoperative Case Selection in the Training of Surgical Repair of Primary Rhegmatogenous Retinal Detachment.

Purpose: To analyse single-operation anatomical success (SOAS) of primary rhegmatogenous retinal detachment (RRD) repair by junior vitreoretinal surgeons guided by preoperative individual case selection by an experienced mentor vitreoretinal surgeon. Methods: Retrospective, single institute, observational study, included all patients who underwent standard pars plana vitrectomy (PPV) or combined encircling band (CB) and PPV and gas tamponade in the treatment of RRD from November 2021 to December 2022 were included. Preoperative selection for the surgery decision, whether standard PPV or combined CB & PPV was undertaken through the senior surgeon; according to the location and extensions of the RRD, number of retinal tears (RT) and lens status. We excluded patients with tractional retinal detachment, RD with proliferative vitreoretinopathy stage C, giant tears, trauma, previous scleral buckle, schisis RD and RD requiring silicone oil. The primary outcome measure was to evaluate the single-operation anatomic success (SOAS). Secondary outcome measures evaluated whether there was a statistical significant difference between both procedures. Results: Eighty-two eyes were included in the study. Forty-five eyes were selected for combined CB&PPV and 37 eyes for standard PPV. SOAS was achieved in 40 eyes (88.8%) in combined group and 35 eyes (94.5%) in standard PPV group. There was no statistically significant difference in the success rate between both operations, p = 0.65. Conclusion: Structured preoperative selection of standardized surgical techniques according to the degree of complexity of RD together with close supervision enables junior vitreoretinal surgeons in training to achieve re-attachment rates of more than 80% with both types of surgeries.

Morphological Macular Changes Under Brolucizumab Treatment for Neovascular Age-Related Macular Degeneration Refractory to Previous Anti-VEGF Treatment Compared with Treatment-Naive Eyes.

Purpose: To evaluate the morphological macular changes and fluid dynamics under brolucizumab treatment in eyes refractory to previous anti-vascular endothelial growth factor (anti-VEGF) treatment for neovascular age-related macular degeneration (nAMD) compared with treatment-naive eyes. Methods: Retrospective study of all eyes treated with brolucizumab for nAMD between 2020 and 2021 with a fixed injection regimen and one year follow-up. Treatment-naive eyes (TN) were compared with eyes refractory to previous treatment with bevacizumab, ranibizumab, or aflibercept (RT). The primary outcome measure was change of best-corrected visual acuity (BCVA). Secondary outcome measures included foveal central thickness (FCT), presence of intra- or subretinal fluid (IRF, SRF) and presence of pigment epithelial detachment (PED) at any time point during treatment in both groups. Results: Seventeen TN eyes and 17 RT eyes were included. Mean BCVA and mean FCT in TN eyes had significantly improved after 3 months and continued to improve during treatment (p<0.05 and p=0.001, respectively). In RT eyes, mean BCVA did not change significantly while mean FCT had improved after 3 months of treatment and remained stable thereafter. SRF or PED were more frequent in RT eyes compared with TN eyes (p=0.003 and p=0.005, respectively). Conclusion: After 3 months of treatment, the BCVA increased significantly only in TN eyes, while the FCT was significantly reduced in both groups. IRF appears to be similarly seen in both groups after the loading phase; however, SRF and PED appear to be more frequent in the RT eyes compared with TN eyes.

Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma.

We treated 26 eyes of 25 young patients having a mean age of 30 years with intravitreal vascular endothelial growth factor (VEGF) inhibitor for choroidal new vessel (CNV) formation overlying choroidal osteoma over a mean follow-up of 26 months. Mean number of injections was 2.4 at 6 months, 3.2 at 12 months, and 5.5 at 24 months. CNV was subfoveal in 14 eyes, juxtafoveal in 5, extrafoveal in 5, and peripapillary in 2. By paired comparison, mean decrease from baseline was 119.7 microns at 6 months (n = 15; P = 0.001), 105.3 microns at 1 year (n = 10; P = 0.03), and 157.6 microns at 2 years (n = 7; P = 0.08). BCVA improved by 3.3 lines at 6 months after therapy (n = 26; P < 0.001), 2.8 lines (n = 20; P = 0.01) at 1 year, and 3.1 lines (n = 13; P = 0.049) at 2 years. We conclude that intravitreal anti-VEGF injections improve vision in majority of eyes with CNV from choroidal osteoma.

Intravitreous injection of bevacizumab, tissue plasminogen activator, and gas in the treatment of submacular hemorrhage in age-related macular degeneration.

PURPOSE: To investigate the benefit of adding bevacizumab to intravitreal recombinant tissue plasminogen activator (rTPA) and gas as initial therapy in subretinal hemorrhage and choroidal neovascularization because of age-related macular degeneration. METHODS: Thirty-eight consecutive patients with recent (1-31 days) subretinal hemorrhage who were treated with intravitreal rTPA and gas (26 patients) or with intravitreal bevacizumab, rTPA, and gas (12 patients) were included in this retrospective analysis. In all patients, a standardized antivascular endothelial growth factor therapy was followed. Testing of best-corrected visual acuity, biomicroscopy, and fundus examination were performed at 4 weeks and 7 months. RESULTS: The mean pretreatment best-corrected visual acuity in the rTPA/gas group was 0.08 ± 0.09 and 0.12 ± 0.13 in the bevacizumab/rTPA/gas group. After 4 weeks, it was significantly higher in the bevacizumab/rTPA/gas group (0.25 ± 0.26) than in the rTPA/gas (0.08 ± 0.1) group (P < 0.05). Also, after 7 months, best-corrected visual acuity was significantly higher in the bevacizumab/rTPA/gas group (0.07 ± 0.07 vs. 0.24 ± 0.35; P < 0.05). Reading vision could be restored in 0% (rTPA/gas) versus 50% (bevacizumab/rTPA/gas). Stabilization (0 ± 2 lines) or improvement of best-corrected visual acuity was obtained in 62% (rTPA/gas) versus 84% (bevacizumab/rTPA/gas). CONCLUSION: From our retrospective pilot study, there is a strong indication that the addition of intravitreal bevacizumab is safe and superior to the displacement of submacular hemorrhages alone with rTPA and gas.

Subclinical choroidal detachment at sclerotomy sites after 23-gauge vitrectomy: analysis by anterior segment optical coherence tomography.

PURPOSE: Transient ocular hypotony commonly occurs after 23-gauge (23G) vitrectomy. To assess possible causes, we visualized the sclerotomy site and pars plana by anterior segment optical coherence tomography (AS-OCT). PROCEDURES: We prospectively analyzed the intraocular pressure (IOP) and findings related to clinical hypotony, assessed by AS-OCT, in 13 consecutive eyes of 13 patients receiving 23G vitrectomy. Five patients receiving a 20G vitrectomy served as controls. RESULTS: The mean IOP after 23G vitrectomy was 11 mm Hg (range: 5-32 mm Hg; 13 eyes) at postoperative day 1. In contrast to controls, AS-OCT showed a scleral gap at the incision site in 22/39 sclerotomies (10/13 eyes), and subclinical choroidal detachment in 9/13 eyes. CONCLUSIONS: A scleral gap and choroidal detachment at the incision site are frequent findings following 23G vitrectomy. These subclinical features may account for postoperative hypotony as they are absent in 20G vitrectomy and scleral sutures. Hypotony following 23G vitrectomy is a self-limiting phenomenon and usually does not require therapeutic intervention.

Retinal thickness in diabetic retinopathy: comparison of optical coherence tomography, the retinal thickness analyzer, and fundus photography.

BACKGROUND: Optical coherence tomography (OCT) and the retinal thickness analyzer (RTA) have proved their ability to measure retinal thickness in healthy subjects and diabetics reliably. In the present study, both techniques were compared for the same study population of diabetic patients, and the findings were related to macular edema shown by stereo fundus photography (SFP). METHODS: Maculas of 124 eyes from 69 patients with diabetes mellitus were examined with OCT and the RTA. Measurements of retinal thickness were compared with signs of macular edema shown by SFP. For each eye, nine different sectors were analyzed (a foveal sector, four parafoveal sectors, and four extrafoveal sectors). Thirteen eyes with a normal macula served as controls. Sensitivity and specificity of detecting clinically significant macular edema (CSME) were calculated. RESULTS: Of 111 eyes, 64 showed signs of CSME by SFP. Mean retinal thickness +/- SD of the foveal sector was 249 +/- 104 microm by RTA and 295 +/- 124 microm by OCT measurements. There was a moderate overall correlation between OCT and the RTA (r = 0.66). The correlation was best in the foveal sector (r = 0.82). Overall correlation with SFP was better for OCT (r = 0.77) than for the RTA (r = 0.62). Sensitivity of detecting CSME was consistently higher with OCT, while the RTA showed higher specificity. CONCLUSION: Both measuring techniques yielded similar results when examining eyes of patients with diabetes, although absolute values differed. OCT seems to be more suitable in the clinical screening for macular edema due to its high sensitivity (>90%) with appropriate analysis parameters. The RTA is more prone to erroneous or missing thickness readings particularly under difficult measuring conditions.

Changes in macular thickness and depth of anterior chamber in patients after filtration surgery.

BACKGROUND: The prospective study was undertaken to analyze retinal thickness of the macula and anterior chamber depth in patients undergoing filtration surgery at different times of follow-up. METHODS: Forty-four patients (45 eyes) were included. The thickness of the fovea and the extrafoveal retina were measured using optical coherence tomography (OCT). Anterior chamber depth was determined using the IOLMaster. All standard clinical examination and measurements were performed prior to surgery, at the 2nd day (1-3 days), 1 week, 1 month and 3 months after surgery. RESULTS: Preoperative IOP under topical medication was 25.5+/-7.5 mmHg. IOP was significantly decreased at all postoperative visits ( P<0.0001): 10.8+/-5.9 mmHg at the 2nd day, 10.4+/-5.2 mmHg after 1 week, 11.7+/-4.4 mmHg after 1 month and 11.4+/-3.6 mmHg after 3 months. No patient in our study suffered from prolonged postoperative hypotony (IOP<5 mmHg). Foveal thickness at the 2nd day, 1 week and 1 month were elevated compared with baseline ( P<0.004). Macular thickness changed from 164+/-20 microm before surgery to 168+/-20 microm after 2 days, 170+/-21 microm after 1 week, 173+/-19 microm after 1 month and 165+/-16 microm after 3 months. Mean thickness of the extrafoveal retina did not change significantly. Also, there were no significant changes in anterior chamber depth. There was no significant correlation between reduction of IOP and retinal thickness or anterior chamber depth. CONCLUSION: The reduction of IOP after filtration surgery leads to a moderate increase in foveal retinal thickness over approximately 1 month and is not associated with shallowing of the anterior chamber, provided that prolonged postoperative hypotony is avoided with the surgical technique used.

Retinal thickness in diabetic retinopathy: a study using optical coherence tomography (OCT).

BACKGROUND AND OBJECTIVE: The authors conducted a controlled study to quantify macular retinal thickness in diabetic retinopathy using optical coherence tomography (OCT) as an objective and noninvasive tool. The relationship between retinal thickness and standard methods of evaluating macular edema was investigated. PATIENTS AND METHODS: A total of 136 patients in different stages of diabetic retinopathy were examined with OCT. In addition, fluorescein angiograms as well as standard eye examinations were conducted. The control group consisted of 30 individuals with a normal macula. RESULTS: In the controls, retinal thickness was 153 +/- 15 microm in the fovea, 249 +/- 19 microm in the temporal parafoveal region, and 268 +/- 20 microm in the nasal parafoveal region. In diabetic patients, retinal thickness was increased to 307 +/- 136 microm in the fovea, 337 +/- 88 microm in the temporal retina, and 353 +/- 95 microm in the nasal retina, respectively. The differences between diabetics and controls were highly significant (P < 0.001). Retinal thickening correlated with fluorescein leakage in the angiograms to some extent. There was an intermediate correlation between retinal thickness and visual acuity, particularly in patients without macular ischemia. Sensitivity of detecting clinically significant macular edema by measuring foveal retinal thickness was 89% and specificity was 96%. CONCLUSION: Optical coherence tomography allows us to quantify retinal thickness in diabetic retinopathy with excellent reproducibility. OCT is able to detect sight-threatening macular edema with great reliability.